Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010)

International Journal of Antimicrobial Agents

Volumn 41, Issue 4, 2013, Pages 337-342

  Farrell, David J ^a   Flamm, Robert K ^a   Sader, Helio S ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Ceftaroline; cSSTI; Europe; MRSA

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; COMPLICATED SKIN AND SOFT TISSUE INFECTION; DRUG POTENCY; ESCHERICHIA COLI; EUROPE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; ESCHERICHIA COLI; EUROPE; GRAM-POSITIVE COCCI; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84875372745     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.12.013     Document Type: Article

References (10)

1. D. Biek, I.A. Critchley, T.A. Riccobene, and D.A. Thye Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity J Antimicrob Chemother 65 Suppl. 4 2010 iv9 iv16
2. R.N. Jones, R.E. Mendes, and H.S. Sader Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study J Antimicrob Chemother 65 Suppl. 4 2010 iv17 iv31
3. G.R. Corey, M. Wilcox, G.H. Talbot, H.D. Friedland, T. Baculik, and G.W. Witherell Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection Clin Infect Dis 51 2010 641 650
4. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 9th ed. Document M07-A9. Wayne, PA: CLSI; 2012.
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. Document M100-S23. Wayne, PA: CLSI; 2013.
6. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. http://www.eucast.org/clinical-breakpoints/ [accessed 01.01.13].
7. ® package insert 2012. http://www.frx.com/pi/Teflaro-pi.pdf [accessed September 2012].
8. ® package insert 2011. http://www.tygacil. com [accessed September 2012].
9. R.E. Mendes, A. Tsakris, H.S. Sader, R.N. Jones, D. Biek, and P. McGhee Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline J Antimicrob Chemother 67 2012 1321 1324
10. G.L. Drusano Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity J Antimicrob Chemother 65 Suppl. 4 2010 iv33 iv39